Acnetane (Isotretinoin): Understanding Treatment for Severe Acne

Acnetane is a brand of isotretinoin (13-cis-retinoic acid), a potent oral retinoid reserved for severe, recalcitrant nodulocystic acne or acne causing scarring/psychological distress. It targets all four pathogenic pillars of acne.

Mechanism of Action

• Sebaceous gland suppression: Reduces size/sebum output by 90% (dose-dependent, reversible)
• Normalizes follicular keratinization: Prevents microcomedone formation
• Anti-inflammatory: Inhibits neutrophil chemotaxis, TLR-2 expression
• Reduces C. acnes: Indirect via sebum reduction (anaerobic environment lost)

Indications

• Severe nodulocystic acne unresponsive to conventional therapy (topicals + oral antibiotics ≥3 months)
• Moderate acne with scarring or significant psychosocial impact
• Acne fulminans (with systemic steroids initially)
• Gram-negative folliculitis

Dosing & Duration

• Cumulative dose target: 120–150 mg/kg (higher → lower relapse)
• Typical regimen: 0.5–1.0 mg/kg/day (often start 0.5, titrate) × 16–24 weeks
• Low-dose/Intermittent regimens: Emerging for maintenance/relapse prevention; less evidence

Critical Safety Program: iPLEDGE (US)

• Mandatory registration for prescribers, pharmacies, patients
• Pregnancy prevention: Category X — teratogenic (CNS, cardiac, thymic defects). Two negative pregnancy tests before start, monthly during, 1 month after. Two contraception forms required.
• Lipid, LFT, CBC monitoring baseline, 1 month, then quarterly

Common Side Effects (≥10%)

• Cheilitis (95%) — universal; lip balm mandatory
• Xerosis, xerophthalmia, epistaxis, dermatitis
• Photosensitivity — broad-spectrum SPF 30+ essential
• Elevated triglycerides (25–50%), transaminitis (10–15%)
• Myalgias/arthralgias (15–20%)

Serious but Rare

• Inflammatory bowel disease flare/new onset (controversial association)
• Depression/suicidality (monitor; no causal proof)
• Intracranial hypertension (pseudotumor cerebri) — with tetracyclines
• Night vision impairment (usually reversible)

Post-Treatment

• Acne may improve further 1–3 months post-course
• Relapse rate: ~30% at 3 years; retreatment effective
• Maintenance: topical retinoids ± benzoyl peroxide

Isotretinoin is transformative for severe acne. Rigorous monitoring and pregnancy prevention are non-negotiable. Managed by experienced dermatologists.